非肿块型及肿块型乳腺癌与其分子生物学标记物相关性研究

Study on the correlation between non-lump and lump breast cancer and its molecular biological markers

目的:探讨非肿块型及肿块型乳腺癌分子生物学标记物表达的差异及两者的生物学特性。方法:回顾性分析2018年1月—2019年1月经病理确诊的31例乳腺癌患者(其中非肿块型乳腺癌15例,肿块型乳腺癌16例)的临床资料,通过免疫组织化学测定癌细胞的雌激素受体(ER)、人表皮生长因子受体-2(HER-2)、孕激素受体(PR)和Ki-67的表达情况,对比非肿块型及肿块型乳腺癌分子生物学标记物表达的差异。结果:非肿块型及肿块型乳腺癌中ER,PR,HER-2阳性率对比差异无统计学意义(P>0.05);非肿块型乳腺癌患者Ki-67的阳性率低于肿块型乳腺癌患者,差异有统计学意义(P<0.05)。结论:非肿块型乳腺癌患者和肿块型乳腺癌患者的ER,PR,HER-2表达存在重叠,但是Ki-67的表达存在不同,说明两者的生物学特性存在差异性。

Objective:To study the differences in the expression of molecular biomarkers of non-lump type and mass type breast cancer,and to explore their biological characteristics.Methods:A retrospective analysis of 31 breast cancer patients(including 15 non-lump breast cancer and 16 lump breast cancer)diagnosed pathologically in hospital from January 2018 to January 2019.The cancer cells were obtained by immunohistochemistry.Comparison the difference of estrogen receptor(ER),human epidermal growth factor receptor-2(HER-2),progesterone receptor(PR)and Ki-67 indicators for the expression of molecular biomarkers in non-lump and mass breast cancer.Results:There was no significant difference in ER,PR,and HER-2 positive rates in non-lump type and lump type breast cancer(P>0.05),the Ki-67 positive rate in non-lump type breast cancer patients was lower than that in lump type breast cancer patients.The comparison between the two is statistically significant(P<0.05).Conclusion:The expression of ER,PR,HER-2 in patients with non-bulky breast cancer and patients with lump breast cancer overlap,but the expression of Ki-67 is different,indicating that the biological characteristics of the two are different.